OpGen, Inc. OPGN · Stock Open OpGen, Inc. in new tab
OpGen, Inc. Analysis (OPGN)
Is OpGen, Inc. a good investment? OpGen, Inc. (OPGN) is currently trading at 23.91 USD.
In terms of valuation, the stock trades at a P/E ratio of 137.50. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: OpGen, Inc. is expected to release its next earnings report on April 2, 2026. The market consensus estimate for Forward EPS is -0.29.
Investor FAQ
Does OpGen, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is OpGen, Inc.?
OpGen, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 2, 2026. The company currently has a trailing EPS of 0.18.
Company Profile
CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. CapForce Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 19, 2018 | 1:25 |
| Aug. 29, 2019 | 1:20 |
| Jan. 5, 2023 | 1:20 |
| May 20, 2024 | 1:10 |
Community Discussion